Misplaced Pages

This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Guanabenz" – news · newspapers · books · scholar · JSTOR (September 2014) (Learn how and when to remove this message)

Guanabenz

Clinical data
Trade names	Wytensin
AHFS/Drugs.com	Consumer Drug Information
MedlinePlus	a686003
ATC code	none
Pharmacokinetic data
Protein binding	90%
Elimination half-life	6 hours
Identifiers
IUPAC name 2-(2,6-dichlorobenzylidene)hydrazinecarboximidamide
CAS Number	5051-62-7
PubChem CID	5702063
IUPHAR/BPS	5443
DrugBank	DB00629
ChemSpider	4642445
UNII	GGD30112WC
KEGG	D04375
ChEMBL	ChEMBL420
CompTox Dashboard (EPA)	DTXSID6045666
ECHA InfoCard	100.023.410
Chemical and physical data
Formula	C8H8Cl2N4
Molar mass	231.08 g·mol
3D model (JSmol)	Interactive image
SMILES Clc1cccc(Cl)c1\C=N\N=C(/N)N
InChI InChI=1S/C8H8Cl2N4/c9-6-2-1-3-7(10)5(6)4-13-14-8(11)12/h1-4H,(H4,11,12,14)/b13-4+ Key:WDZVGELJXXEGPV-YIXHJXPBSA-N
(verify)

Guanabenz (pronounced GWAHN-a-benz, sold under the trade name Wytensin) is an alpha agonist that is selective to the alpha-2 adrenergic receptor. Guanabenz is used as an antihypertensive drug used in the treatment of high blood pressure (hypertension).

The most common side effects during guanabenz therapy are dizziness, drowsiness, dry mouth, headache and weakness.

Guanabenz can make one drowsy or less alert, therefore driving or operating dangerous machinery is not recommended.

Research

Guanabenz also has some anti-inflammatory properties in different pathological situations, including multiple sclerosis.

Guanabenz was found in one study to exert an inhibitory effect by decreasing the abundance of the enzyme CH25H, a cholesterol hydroxylase linked to antiviral immunity. Therefore, it is suggested that the drug and similar compounds could be used to treat type I interferon-dependent pathologies and that the CH25H enzyme could be a therapeutic target to control these diseases, including amyotrophic lateral sclerosis.

See also

• Guanoxabenz
• Guanfacine

References

1. Walker BR, Hare LE, Deitch MW (1982). "Comparative antihypertensive effects of guanabenz and clonidine". The Journal of International Medical Research. 10 (1): 6–14. doi:10.1177/030006058201000102. PMID 7037502. S2CID 2139809.
2. Bonham AC, Trapani AJ, Portis LR, Brody MJ (December 1984). "Studies on the mechanism of the central antihypertensive effect of guanabenz and clonidine". Journal of Hypertension Supplement. 2 (3): S543 – S546. PMID 6599714.
3. "Guanabenz | The Merck Index Online". www.rsc.org. Retrieved 2023-04-17.
4. Way SW, Podojil JR, Clayton BL, Zaremba A, Collins TL, Kunjamma RB, et al. (March 2015). "Pharmaceutical integrated stress response enhancement protects oligodendrocytes and provides a potential multiple sclerosis therapeutic". Nature Communications. 6: 6532. Bibcode:2015NatCo...6.6532W. doi:10.1038/ncomms7532. PMC 4360920. PMID 25766071.
5. Perego J, Mendes A, Bourbon C, Camosseto V, Combes A, Liu H, et al. (January 2018). "Guanabenz inhibits TLR9 signaling through a pathway that is independent of eIF2α dephosphorylation by the GADD34/PP1c complex". Science Signaling. 11 (514): eaam8104. doi:10.1126/scisignal.aam8104. hdl:10773/27856. PMID 29363586. S2CID 13680678.

This antihypertensive-related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Alpha-2 adrenergic receptor agonists
• Chloroarenes
• Guanidines
• Antihypertensive agent stubs